摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 3-[(tert-butoxycarbonyl)amino]-2-(methylsulfonyloxy)propanoate | 871936-68-4

中文名称
——
中文别名
——
英文名称
ethyl 3-[(tert-butoxycarbonyl)amino]-2-(methylsulfonyloxy)propanoate
英文别名
Ethyl 3-[(tert-butoxycarbonyl)amino]-2-(methylsulfonyloxy)propanoate;ethyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-methylsulfonyloxypropanoate
ethyl 3-[(tert-butoxycarbonyl)amino]-2-(methylsulfonyloxy)propanoate化学式
CAS
871936-68-4
化学式
C11H21NO7S
mdl
——
分子量
311.356
InChiKey
CVRONJADUHJBRI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    20
  • 可旋转键数:
    9
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    116
  • 氢给体数:
    1
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Hiv Integrase Inhibitors
    申请人:Wai S. John
    公开号:US20080015187A1
    公开(公告)日:2008-01-17
    Bicyclic pyrazoles of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein Z is O or N(R 8 ); n is an integer equal to zero or 1; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    式I中的双环吡唑是HIV整合酶的抑制剂和HIV复制的抑制剂:其中Z是O或N(R8); n是等于零或1的整数; R1、R2、R3、R4、R5、R6、R7和R8在此定义。这些化合物对预防和治疗HIV感染以及预防、延迟发病和治疗艾滋病非常有用。这些化合物可作为化合物本身或以药学上可接受的盐的形式用于对抗HIV感染和艾滋病。这些化合物及其盐可作为药物组成部分,可与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。
  • HIV integrase inhibitors
    申请人:Merck & Co., Inc.
    公开号:US07476666B2
    公开(公告)日:2009-01-13
    Bicyclic pyrazoles of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein Z is O or N(R8); n is an integer equal to zero or 1; and R1, R2, R3, R4, R5, R6, R7 and R8 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    化合物I式的双环吡唑是HIV整合酶的抑制剂和HIV复制的抑制剂:其中Z为O或N(R8); n是等于零或1的整数; R1,R2,R3,R4,R5,R6,R7和R8在此定义。这些化合物在预防和治疗HIV感染以及预防,延迟发病和治疗艾滋病方面非常有用。这些化合物可作为化合物本身或以药学上可接受的盐的形式用于抗击HIV感染和艾滋病。这些化合物及其盐可作为制药组合物中的成分,可与其他抗病毒药物,免疫调节剂,抗生素或疫苗组合使用。
  • Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors
    作者:H. Marie Langford、Peter D. Williams、Carl F. Homnick、Joseph P. Vacca、Peter J. Felock、Kara A. Stillmock、Marc V. Witmer、Daria J. Hazuda、Lori J. Gabryelski、William A. Schleif
    DOI:10.1016/j.bmcl.2007.11.049
    日期:2008.1
    A series of 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides was synthesized and tested for their inhibition of HIV-1 integrase catalytic activity and HIV-1 replication in cells. Structure-activity studies around lead compound 5 indicated that a coplanar relationship of metal-binding heteroatoms provides optimal binding to the integrase active site. Identification of potency-enhancing substituents and adjustments in lipophilicity provided 17b which inhibits integrase-catalyzed strand transfer with an IC50 value of 74 nM and inhibits HIV-1 replication in cell culture in the presence of 50% normal human serum with an IC95 value of 63 nM. (c) 2007 Elsevier Ltd. All rights reserved.
  • EP1758585A4
    申请人:——
    公开号:EP1758585A4
    公开(公告)日:2009-07-22
  • HIV INTEGRASE INHIBITORS
    申请人:Merck & Co., Inc.
    公开号:EP1758585A2
    公开(公告)日:2007-03-07
查看更多